首页 > 最新文献

Journal of veterinary pharmacology and therapeutics最新文献

英文 中文
A narrative review of the phenomenon of predatory journals to create awareness among researchers in veterinary medicine 对掠夺性期刊现象进行叙述性综述,提高兽医学研究人员的认识。
IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-23 DOI: 10.1111/jvp.13448
Charbel Fadel, Aneliya Milanova, Jelena Suran, Andrejs Sitovs, Tae Won Kim, Abubakar Bello, Solomon Mequanente Abay, Stefanie Horst, Rositsa Mileva, Michela Amadori, Ena Oster, Giovanni Re, Arifah Abdul Kadir, Graziana Gambino, Cristina Vercelli

In recent years, especially since the COVID-19 pandemic, the number of predatory journals has increased significantly. Predatory journals exploit the “open-access model” by engaging in deceptive practices such as charging high publication fees without providing the expected quality and performing insufficient or no peer review. Such behaviors undermine the integrity of scientific research and can result in researchers having trouble identifying reputable publication opportunities, particularly early-career researchers who struggle to understand and establish the correct criteria for publication in reputable journals. Publishing in journals that do not fully cover the criteria for scientific publication is also an ethical issue. This review aimed to describe the characteristics of predatory journals, differentiate between reliable and predatory journals, investigate the reasons that lead researchers to publish in predatory journals, evaluate the negative impact of predatory publications on the scientific community, and explore future perspectives. The authors also provide some considerations for researchers (particularly early-career researchers) when selecting journals for publication, explaining the role of metrics, databases, and artificial intelligence in manuscript preparation, with a specific focus on and relevance to publication in veterinary medicine.

近年来,特别是 COVID-19 大流行以来,掠夺性期刊的数量大幅增加。掠夺性期刊利用 "开放获取模式",采取欺骗性做法,如收取高额出版费却不提供预期质量,同行评审不足或根本不进行同行评审。这些行为破坏了科学研究的完整性,可能导致研究人员难以找到声誉良好的发表机会,尤其是那些难以理解和建立在声誉良好的期刊上发表论文的正确标准的早期职业研究人员。在不完全符合科学发表标准的期刊上发表论文也是一个道德问题。这篇综述旨在描述掠夺性期刊的特点,区分可靠期刊和掠夺性期刊,调查导致研究人员在掠夺性期刊上发表文章的原因,评估掠夺性出版物对科学界的负面影响,并探讨未来的发展前景。作者还为研究人员(尤其是早期研究人员)提供了选择期刊发表论文时的一些注意事项,解释了指标、数据库和人工智能在稿件准备中的作用,并特别关注兽医学领域的论文发表及其相关性。
{"title":"A narrative review of the phenomenon of predatory journals to create awareness among researchers in veterinary medicine","authors":"Charbel Fadel,&nbsp;Aneliya Milanova,&nbsp;Jelena Suran,&nbsp;Andrejs Sitovs,&nbsp;Tae Won Kim,&nbsp;Abubakar Bello,&nbsp;Solomon Mequanente Abay,&nbsp;Stefanie Horst,&nbsp;Rositsa Mileva,&nbsp;Michela Amadori,&nbsp;Ena Oster,&nbsp;Giovanni Re,&nbsp;Arifah Abdul Kadir,&nbsp;Graziana Gambino,&nbsp;Cristina Vercelli","doi":"10.1111/jvp.13448","DOIUrl":"10.1111/jvp.13448","url":null,"abstract":"<p>In recent years, especially since the COVID-19 pandemic, the number of <i>predatory</i> journals has increased significantly. Predatory journals exploit the “open-access model” by engaging in deceptive practices such as charging high publication fees without providing the expected quality and performing insufficient or no peer review. Such behaviors undermine the integrity of scientific research and can result in researchers having trouble identifying reputable publication opportunities, particularly early-career researchers who struggle to understand and establish the correct criteria for publication in reputable journals. Publishing in journals that do not fully cover the criteria for scientific publication is also an ethical issue. This review aimed to describe the characteristics of predatory journals, differentiate between reliable and predatory journals, investigate the reasons that lead researchers to publish in predatory journals, evaluate the negative impact of predatory publications on the scientific community, and explore future perspectives. The authors also provide some considerations for researchers (particularly early-career researchers) when selecting journals for publication, explaining the role of metrics, databases, and artificial intelligence in manuscript preparation, with a specific focus on and relevance to publication in veterinary medicine.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"239-251"},"PeriodicalIF":1.5,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140667911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics of tilmicosin in plasma, urine and feces after a single intragastric administration in donkey (Equus asinus) 驴(Equus asinus)一次胃内给药后血浆、尿液和粪便中替米考星的药代动力学。
IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-10 DOI: 10.1111/jvp.13446
Bowen Yang, Shijie Liu, Yanxin Guo, Honglei Qu, Yulong Feng, Yantao Wang, Boying Dong, Yanjie Dong, Shancang Zhao, Shimeng Huang, Lihong Zhao, Jianyun Zhang, Cheng Ji, Qiugang Ma

Tilmicosin, a macrolide antibiotic, has the potential to treat bacterial infections in donkeys. However, the pharmacokinetics of tilmicosin in donkeys have not been reported. The aim of this study was to investigate the pharmacokinetics of tilmicosin in donkey plasma, urine, and feces after a single intragastric administration to determine the suitability of tilmicosin for donkeys. A total of 5 healthy male donkeys with similar body weights were selected. The donkeys were administered a single dose of 10 mg · kg−1 body weight (BW) tilmicosin by gavage. The concentrations of tilmicosin in plasma, urine, and feces were determined. The results showed that after a single intragastric administration of 10 mg · kg−1 body weight, tilmicosin in donkey plasma reached a maximum concentration of 11.23 ± 5.37 mg · L−1 at 0.80 ± 0.10 h, with a half-life of 14.49 ± 7.13 h, a mean residence time of 28.05 ± 3.05 h, a Cl/F of 0.48 ± 0.18 L · kg−1 · h−1, and a Vd/F of 9.28 ± 2.63 Lkg−1. The percentage of tilmicosin excreted through the urine of donkeys is 2.47%, and the percentage excreted through the feces is 66.43%. Our study provides data to inform the use of tilmicosin in donkeys.

替米考星是一种大环内酯类抗生素,具有治疗驴细菌感染的潜力。然而,驴体内替米考星的药代动力学尚未见报道。本研究的目的是调查驴一次胃内给药后血浆、尿液和粪便中替米考星的药代动力学,以确定替米考星是否适用于驴。共挑选了 5 头体重相近的健康雄驴。给驴灌胃单剂量 10 毫克-千克-1 体重(BW)替米考星。测定血浆、尿液和粪便中替米考星的浓度。结果表明,一次胃内给药 10 毫克-千克-1 体重后,驴血浆中替米考星的最大浓度在 0.80 ± 0.10 小时内达到 11.23 ± 5.37 毫克-升-1,半衰期为 14.49 ± 7.13 小时,平均停留时间为 28.05 ± 3.05 小时,Cl/F 为 0.48 ± 0.18 升-千克-1 -小时-1,Vd/F 为 9.28 ± 2.63 升-千克-1。通过驴尿排泄的替米考星比例为 2.47%,通过粪便排泄的比例为 66.43%。我们的研究为驴使用替米考星提供了数据依据。
{"title":"Pharmacokinetics of tilmicosin in plasma, urine and feces after a single intragastric administration in donkey (Equus asinus)","authors":"Bowen Yang,&nbsp;Shijie Liu,&nbsp;Yanxin Guo,&nbsp;Honglei Qu,&nbsp;Yulong Feng,&nbsp;Yantao Wang,&nbsp;Boying Dong,&nbsp;Yanjie Dong,&nbsp;Shancang Zhao,&nbsp;Shimeng Huang,&nbsp;Lihong Zhao,&nbsp;Jianyun Zhang,&nbsp;Cheng Ji,&nbsp;Qiugang Ma","doi":"10.1111/jvp.13446","DOIUrl":"10.1111/jvp.13446","url":null,"abstract":"<p>Tilmicosin, a macrolide antibiotic, has the potential to treat bacterial infections in donkeys. However, the pharmacokinetics of tilmicosin in donkeys have not been reported. The aim of this study was to investigate the pharmacokinetics of tilmicosin in donkey plasma, urine, and feces after a single intragastric administration to determine the suitability of tilmicosin for donkeys. A total of 5 healthy male donkeys with similar body weights were selected. The donkeys were administered a single dose of 10 mg · kg<sup>−1</sup> body weight (BW) tilmicosin by gavage. The concentrations of tilmicosin in plasma, urine, and feces were determined. The results showed that after a single intragastric administration of 10 mg · kg<sup>−1</sup> body weight, tilmicosin in donkey plasma reached a maximum concentration of 11.23 ± 5.37 mg · L<sup>−1</sup> at 0.80 ± 0.10 h, with a half-life of 14.49 ± 7.13 h, a mean residence time of 28.05 ± 3.05 h, a Cl/F of 0.48 ± 0.18 L · kg<sup>−1</sup> · h<sup>−1</sup>, and a Vd/F of 9.28 ± 2.63 Lkg<sup>−1</sup>. The percentage of tilmicosin excreted through the urine of donkeys is 2.47%, and the percentage excreted through the feces is 66.43%. Our study provides data to inform the use of tilmicosin in donkeys.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"257-265"},"PeriodicalIF":1.5,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140718849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics of long-acting cephapirin and cloxacillin after intramammary administration in dairy goats 奶山羊乳房内注射长效头孢匹林和氯唑西林的药代动力学。
IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-04 DOI: 10.1111/jvp.13445
Michelle P. Buckley, Kristen P. Hayman, Laura Burns, Dwayne Schrunk, Patrick J. Gorden

Determining the pharmacokinetics of intramammary antimicrobials in goats can assist in predicting appropriate meat and milk withdrawal intervals for drugs that are effective at treating subclinical mastitis due to non-aureus Staphylococci during the dry period. Twenty-four healthy, lactating does were enrolled in this study. Half were administered 300 mg of cephapirin benzathine (ToMORROW, Boehringer Ingelheim Vetmedica, Duluth, GA) via intramammary infusion into each half of the udder. The remaining does had 500 mg cloxacillin benzathine (Orbenin DC, Merck & Co., Rahway, NJ) administered per half. Plasma was collected before treatment and for 7 days post-treatment followed by analysis via liquid chromatography with tandem mass spectroscopy. Pharmacokinetic parameters were determined using noncompartmental methods via commercial software (MonolixSuite). The mean maximum concentration (C max) of cephapirin of 0.073 μg/mL was noted at 7.06 h post-administration (T max). The area under the plasma concentration curve based on the final sampling point (AUClast) was 1.06 h × μg/mL. The mean residence time until the final sampling point (MRTlast) was 13.55 h. Mean terminal half-life (T ½) of cephapirin was 6.98 h. In CLOX does, C max was 0.074 μg/mL with a T max of 18 h, AUClast was 5.71 h × μg/mL, T ½ was 77.45 h, and MRTlast was 65.36 h. Despite both products being formulated with benzathine salts, marked differences were noted in pharmacokinetic parameters including AUC, T 1/2, and MRTlast. This data will be used to plan sampling schedules for milk and tissue residue depletion studies for both products.

确定山羊乳房内抗菌药的药代动力学有助于预测适当的停肉和停奶时间间隔,这些药物可有效治疗干奶期由非金黄色葡萄球菌引起的亚临床乳腺炎。24 头健康的泌乳母山羊参加了这项研究。一半的母鹿通过乳房内输注的方式在乳房两侧各注射了 300 毫克的苄星头孢匹林(ToMORROW,勃林格殷格翰兽医公司,德卢斯,佐治亚州)。其余的母牛每半边乳房注射 500 毫克氯唑西林苄星青霉素(Orbenin DC,默克公司,新泽西州拉威)。在治疗前和治疗后 7 天收集血浆,然后通过液相色谱法和串联质谱法进行分析。药代动力学参数是通过商用软件(MonolixSuite)采用非室方法测定的。给药后 7.06 小时(Tmax),头孢匹林的平均最大浓度(Cmax)为 0.073 μg/mL。基于最终采样点的血浆浓度曲线下面积(AUClast)为 1.06 h × μg/mL。在 CLOX 试验中,Cmax 为 0.074 μg/mL,Tmax 为 18 h,AUClast 为 5.尽管两种产品都使用苄星盐配制,但在药代动力学参数(包括 AUC、T1/2 和 MRTlast)方面存在明显差异。这些数据将用于规划两种产品的牛奶和组织残留消耗研究的采样计划。
{"title":"Pharmacokinetics of long-acting cephapirin and cloxacillin after intramammary administration in dairy goats","authors":"Michelle P. Buckley,&nbsp;Kristen P. Hayman,&nbsp;Laura Burns,&nbsp;Dwayne Schrunk,&nbsp;Patrick J. Gorden","doi":"10.1111/jvp.13445","DOIUrl":"10.1111/jvp.13445","url":null,"abstract":"<p>Determining the pharmacokinetics of intramammary antimicrobials in goats can assist in predicting appropriate meat and milk withdrawal intervals for drugs that are effective at treating subclinical mastitis due to non-aureus <i>Staphylococci</i> during the dry period. Twenty-four healthy, lactating does were enrolled in this study. Half were administered 300 mg of cephapirin benzathine (ToMORROW, Boehringer Ingelheim Vetmedica, Duluth, GA) via intramammary infusion into each half of the udder. The remaining does had 500 mg cloxacillin benzathine (Orbenin DC, Merck &amp; Co., Rahway, NJ) administered per half. Plasma was collected before treatment and for 7 days post-treatment followed by analysis via liquid chromatography with tandem mass spectroscopy. Pharmacokinetic parameters were determined using noncompartmental methods via commercial software (MonolixSuite). The mean maximum concentration (<i>C</i>\u0000 <sub>max</sub>) of cephapirin of 0.073 μg/mL was noted at 7.06 h post-administration (<i>T</i>\u0000 <sub>max</sub>). The area under the plasma concentration curve based on the final sampling point (AUC<sub>last</sub>) was 1.06 h × μg/mL. The mean residence time until the final sampling point (MRT<sub>last</sub>) was 13.55 h. Mean terminal half-life (<i>T</i>\u0000 <sub>½</sub>) of cephapirin was 6.98 h. In CLOX does, <i>C</i>\u0000 <sub>max</sub> was 0.074 μg/mL with a <i>T</i>\u0000 <sub>max</sub> of 18 h, AUC<sub>last</sub> was 5.71 h × μg/mL, <i>T</i>\u0000 <sub>½</sub> was 77.45 h, and MRT<sub>last</sub> was 65.36 h. Despite both products being formulated with benzathine salts, marked differences were noted in pharmacokinetic parameters including AUC, <i>T</i>\u0000 <sub>1/2</sub>, and MRT<sub>last</sub>. This data will be used to plan sampling schedules for milk and tissue residue depletion studies for both products.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 5","pages":"396-402"},"PeriodicalIF":1.5,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13445","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140745171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral cinacalcet administration decreases serum ionized calcium and parathyroid hormone concentrations in healthy dogs 口服西那卡西酮可降低健康犬的血清离子钙和甲状旁腺激素浓度。
IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-02 DOI: 10.1111/jvp.13443
Hannah E. Clark, Lauren A. Trepanier, Michael W. Wood

Cinacalcet is an oral calcimimetic that has potential to non-invasively treat primary hyperparathyroidism in dogs (Canis lupis familiaris). There is minimal data assessing its efficacy in dogs. This study aimed to determine whether a single dose of cinacalcet decreases serum ionized calcium (iCa), total calcium (tCa), and parathyroid hormone (PTH) concentrations. Twelve dogs received a median dose of 0.49 mg/kg (range 0.30–0.69 mg/kg) cinacalcet per os. Venous blood samples were collected at time 0 (before cinacalcet administration), 3, 8, and 24 h following cinacalcet administration. PTH, iCa, and tCa concentrations were measured at each time point and compared to 0 hour concentrations. A significant (50%) decrease in serum PTH occurred at 3 h with a median PTH of 4.6 pmol/L (range 2.7–10.8) at baseline and 1.65 pmol/L (range 0.5–14.7) at 3 h; p = .005. A significant, but not clinically relevant, decrease in serum iCa from a median baseline of 1.340 mmol/L (range 1.32–1.41) to a 3 h median of 1.325 mmol/L (range 1.26–1.39), p = .043, was also observed. tCa concentrations were not different. This study showed that a single dose of cinacalcet leads to transient decreases in iCa and PTH concentrations in healthy dogs.

Cinacalcet 是一种口服钙离子拮抗剂,可用于非侵入性治疗犬(Canis lupis familiaris)原发性甲状旁腺功能亢进症。目前只有极少数数据评估了它在狗体内的疗效。本研究旨在确定单剂量西那卡西酮是否会降低血清离子钙(iCa)、总钙(tCa)和甲状旁腺激素(PTH)的浓度。12 只狗每次口服西那卡西酮的中位剂量为 0.49 毫克/千克(范围为 0.30-0.69 毫克/千克)。分别在给药前、给药后 3、8 和 24 小时采集静脉血样本。在每个时间点测量 PTH、iCa 和 tCa 的浓度,并与 0 小时的浓度进行比较。血清 PTH 在 3 小时后明显下降(50%),基线 PTH 中位数为 4.6 pmol/L(范围 2.7-10.8),3 小时后为 1.65 pmol/L(范围 0.5-14.7);P = 0.005。此外,还观察到血清 iCa 从基线中位数 1.340 mmol/L(范围 1.32-1.41)降至 3 小时中位数 1.325 mmol/L(范围 1.26-1.39),p = .043。该研究表明,单剂量西那卡西酮可导致健康犬体内 iCa 和 PTH 浓度的短暂下降。
{"title":"Oral cinacalcet administration decreases serum ionized calcium and parathyroid hormone concentrations in healthy dogs","authors":"Hannah E. Clark,&nbsp;Lauren A. Trepanier,&nbsp;Michael W. Wood","doi":"10.1111/jvp.13443","DOIUrl":"10.1111/jvp.13443","url":null,"abstract":"<p>Cinacalcet is an oral calcimimetic that has potential to non-invasively treat primary hyperparathyroidism in dogs (<i>Canis lupis familiaris</i>). There is minimal data assessing its efficacy in dogs. This study aimed to determine whether a single dose of cinacalcet decreases serum ionized calcium (iCa), total calcium (tCa), and parathyroid hormone (PTH) concentrations. Twelve dogs received a median dose of 0.49 mg/kg (range 0.30–0.69 mg/kg) cinacalcet per os. Venous blood samples were collected at time 0 (before cinacalcet administration), 3, 8, and 24 h following cinacalcet administration. PTH, iCa, and tCa concentrations were measured at each time point and compared to 0 hour concentrations. A significant (50%) decrease in serum PTH occurred at 3 h with a median PTH of 4.6 pmol/L (range 2.7–10.8) at baseline and 1.65 pmol/L (range 0.5–14.7) at 3 h; <i>p</i> = .005. A significant, but not clinically relevant, decrease in serum iCa from a median baseline of 1.340 mmol/L (range 1.32–1.41) to a 3 h median of 1.325 mmol/L (range 1.26–1.39), <i>p</i> = .043, was also observed. tCa concentrations were not different. This study showed that a single dose of cinacalcet leads to transient decreases in iCa and PTH concentrations in healthy dogs.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"274-279"},"PeriodicalIF":1.5,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13443","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140336072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics of intraarticular liposomal amphotericin B in goats (Capra aegagrus hircus) 山羊(Capra aegagrus hircus)关节内脂质体两性霉素 B 的药代动力学。
IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-01 DOI: 10.1111/jvp.13442
Joe S. Smith, Grace D. Malla, Jessica D. Garcia, Jessica E. Gebert, Charlene V. Noll, Pierre-Yves Mulon, Heather K. Knych

Lameness is a significant welfare concern in goats. Amphotericin B is used via intraarticular (IA) administration in models to study experimentally induced lameness in large animals. The main objective of this study was to estimate plasma pharmacokinetic (PK) parameters for amphotericin B in goats after a single IA administration. Liposomal amphotericin B was administered to ten Kiko-cross goats at a dose of 10 mg total (range: 0.34–0.51 mg/kg) via IA administration into the right hind lateral distal interphalangeal joint. Plasma samples were collected over 96 h. Amphotericin B concentrations were measured via liquid chromatography/mass spectrometry (LC–MS/MS). A non-compartmental analysis was used to derive PK parameters. Following single IA administration, maximum plasma concentration was estimated at 54.6 ± 16.5 ng/mL, and time to maximum concentration ranged from 6 to 12 h. Elimination half-life was estimated at 30.9 ± 16.5 h, and mean residence time was 45.1 ± 10.4 h. The volume of distribution after IA administration was 13.3 ± 9.4 L/kg. The area under the curve was 1481 ± 761 h*ng/mL. The achieved maximum concentration was less than the observed concentrations for other species and routes of administration. Further research is needed into the pharmacodynamics of IA liposomal amphotericin B in goats to determine specific research strategies.

跛足是山羊的一个重要福利问题。两性霉素 B 可通过关节内给药用于研究大型动物实验性跛行的模型。本研究的主要目的是估算山羊一次IA给药后两性霉素B的血浆药代动力学(PK)参数。通过在右后外侧远端指间关节内注射两性霉素 B 脂质体,给 10 只 Kiko 杂交山羊注射了总剂量为 10 毫克(范围:0.34-0.51 毫克/千克)的两性霉素 B 脂质体。通过液相色谱/质谱法(LC-MS/MS)测量两性霉素 B 的浓度。采用非室分析法得出 PK 参数。单次给药后,最大血浆浓度估计为 54.6 ± 16.5 纳克/毫升,达到最大浓度的时间为 6 至 12 小时。曲线下面积为 1481 ± 761 h*ng/mL。所达到的最大浓度低于其他物种和给药途径的观察浓度。需要进一步研究山羊体内两性霉素 B 脂质体的药效学,以确定具体的研究策略。
{"title":"Pharmacokinetics of intraarticular liposomal amphotericin B in goats (Capra aegagrus hircus)","authors":"Joe S. Smith,&nbsp;Grace D. Malla,&nbsp;Jessica D. Garcia,&nbsp;Jessica E. Gebert,&nbsp;Charlene V. Noll,&nbsp;Pierre-Yves Mulon,&nbsp;Heather K. Knych","doi":"10.1111/jvp.13442","DOIUrl":"10.1111/jvp.13442","url":null,"abstract":"<p>Lameness is a significant welfare concern in goats. Amphotericin B is used via intraarticular (IA) administration in models to study experimentally induced lameness in large animals. The main objective of this study was to estimate plasma pharmacokinetic (PK) parameters for amphotericin B in goats after a single IA administration. Liposomal amphotericin B was administered to ten Kiko-cross goats at a dose of 10 mg total (range: 0.34–0.51 mg/kg) via IA administration into the right hind lateral distal interphalangeal joint. Plasma samples were collected over 96 h. Amphotericin B concentrations were measured via liquid chromatography/mass spectrometry (LC–MS/MS). A non-compartmental analysis was used to derive PK parameters. Following single IA administration, maximum plasma concentration was estimated at 54.6 ± 16.5 ng/mL, and time to maximum concentration ranged from 6 to 12 h. Elimination half-life was estimated at 30.9 ± 16.5 h, and mean residence time was 45.1 ± 10.4 h. The volume of distribution after IA administration was 13.3 ± 9.4 L/kg. The area under the curve was 1481 ± 761 h*ng/mL. The achieved maximum concentration was less than the observed concentrations for other species and routes of administration. Further research is needed into the pharmacodynamics of IA liposomal amphotericin B in goats to determine specific research strategies.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"252-256"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140336073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative disposition kinetics of oral deracoxib in sheep and goats 绵羊和山羊口服德拉克西布的处置动力学比较。
IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-28 DOI: 10.1111/jvp.13444
Charbel Fadel, Beata Łebkowska-Wieruszewska, Andrzej Lisowski, Firas Serih, Amnart Poapolathep, Mario Giorgi

This study investigates the pharmacokinetics (PK) of deracoxib (DX), a selective COX-2 inhibitor, in sheep and goats following a single oral dose. DX, approved for dogs, holds potential as an alternative NSAID in small ruminants, particularly in light of heightened concern regarding abomasal ulceration. The study employed an oral administration of DX at a dose of 150 mg/head (sheep and goats), and plasma concentrations were determined after validating a high-performance liquid chromatography method, coupled to a UV detector. The PK parameters, including maximum plasma concentration (C max), time to reach C max (T max), elimination half-life (t 1/2), and area under the curve (AUC), were evaluated through non-compartmental analysis. Results showed detectable DX in plasma up to 48 h, with no observed adverse effects. No significant differences in any PK parameters were noted between sheep and goats. Notably, t 1/2 values were relatively long, at 16.66 h for sheep and 22.86 h for goats. Despite the fact that both species exhibited comparable drug exposure, high individual variability was noted within each species, suggesting to take into account individual variations in response to DX treatment, rather than species-specific considerations. Additional research involving pharmacodynamics and multiple-dose studies is warranted to comprehensively assess the profile of DX in these species.

本研究调查了选择性 COX-2 抑制剂德拉克昔布 (DX) 在绵羊和山羊中单次口服后的药代动力学 (PK)。DX已被批准用于狗,有望成为小反刍动物的替代非甾体抗炎药,特别是考虑到人们对腹腔溃疡的高度关注。该研究采用了口服DX的方法,剂量为150毫克/头(绵羊和山羊),在验证了高效液相色谱法和紫外检测器后测定了血浆浓度。通过非室分析评估了PK参数,包括最大血浆浓度(Cmax)、达到Cmax的时间(Tmax)、消除半衰期(t1/2)和曲线下面积(AUC)。结果显示,血浆中可检测到的 DX 达 48 小时,未观察到不良反应。绵羊和山羊的任何 PK 参数均无明显差异。值得注意的是,t1/2值相对较长,绵羊为16.66小时,山羊为22.86小时。尽管两个物种的药物暴露量相当,但每个物种的个体差异都很大,这表明应考虑到个体对 DX 治疗的反应差异,而不是特定物种的考虑因素。要全面评估 DX 在这些物种中的特性,还需要进行更多涉及药效学和多剂量研究的研究。
{"title":"Comparative disposition kinetics of oral deracoxib in sheep and goats","authors":"Charbel Fadel,&nbsp;Beata Łebkowska-Wieruszewska,&nbsp;Andrzej Lisowski,&nbsp;Firas Serih,&nbsp;Amnart Poapolathep,&nbsp;Mario Giorgi","doi":"10.1111/jvp.13444","DOIUrl":"10.1111/jvp.13444","url":null,"abstract":"<p>This study investigates the pharmacokinetics (PK) of deracoxib (DX), a selective COX-2 inhibitor, in sheep and goats following a single oral dose. DX, approved for dogs, holds potential as an alternative NSAID in small ruminants, particularly in light of heightened concern regarding abomasal ulceration. The study employed an oral administration of DX at a dose of 150 mg/head (sheep and goats), and plasma concentrations were determined after validating a high-performance liquid chromatography method, coupled to a UV detector. The PK parameters, including maximum plasma concentration (<i>C</i>\u0000 <sub>max</sub>), time to reach <i>C</i>\u0000 <sub>max</sub> (<i>T</i>\u0000 <sub>max</sub>), elimination half-life (<i>t</i>\u0000 <sub>1/2</sub>), and area under the curve (AUC), were evaluated through non-compartmental analysis. Results showed detectable DX in plasma up to 48 h, with no observed adverse effects. No significant differences in any PK parameters were noted between sheep and goats. Notably, <i>t</i>\u0000 <sub>1/2</sub> values were relatively long, at 16.66 h for sheep and 22.86 h for goats. Despite the fact that both species exhibited comparable drug exposure, high individual variability was noted within each species, suggesting to take into account individual variations in response to DX treatment, rather than species-specific considerations. Additional research involving pharmacodynamics and multiple-dose studies is warranted to comprehensively assess the profile of DX in these species.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 5","pages":"390-395"},"PeriodicalIF":1.5,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140306027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics of subcutaneous ketamine administration via the Omnipod® system in dogs 通过 Omnipod® 系统在狗身上皮下注射氯胺酮的药代动力学。
IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-27 DOI: 10.1111/jvp.13440
Claudia Colón, Peter Early, Karen Muñana, Natasha Olby, Christopher Mariani, Shelby Mancini, Gilad Fefer, Zhong Li, Jessica Briley, Kate Bailey, Duncan Lascelles, Kristen Messenger

Ketamine is an injectable anesthetic agent with analgesic and antidepressant effects that can prevent maladaptive pain. Ketamine is metabolized by the liver into norketamine, an active metabolite. Prior rodent studies have suggested that norketamine is thought to contribute up to 30% of ketamine's analgesic effect. Ketamine is usually administered as an intravenous (IV) bolus injection or continuous rate infusion (CRI) but can be administered subcutaneously (SC) and intramuscularly (IM). The Omnipod® is a wireless, subcutaneous insulin delivery device that adheres to the skin and delivers insulin as an SC CRI. The Omnipod® was used in dogs for postoperative administration of ketamine as a 1 mg/kg infusion bolus (IB) over 1 hour (h). Pharmacokinetics (PK) showed plasma ketamine concentrations between 42 and 326.1 ng/mL. The median peak plasma concentration was 79.5 (41.9–326.1) ng/mL with a Tmax of 60 (30–75) min. After the same infusion bolus, the corresponding norketamine PK showed plasma drug concentrations between 22.0 and 64.8 ng/mL. The median peak plasma concentration was 43.0 (26.1–71.8) ng/mL with a median Tmax of 75 min. The median peak ketamine plasma concentration exceeded 100 ng/mL in dogs for less than 1 h post infusion. The Omnipod® system successfully delivered subcutaneous ketamine to dogs in the postoperatively.

氯胺酮是一种可注射的麻醉剂,具有镇痛和抗抑郁作用,可预防适应性疼痛。氯胺酮会在肝脏中代谢为活性代谢物--诺克司他明。先前的啮齿类动物研究表明,氯胺酮的镇痛效果中多达 30% 是由氯胺酮产生的。氯胺酮通常以静脉注射(IV)或持续输注(CRI)的方式给药,但也可以皮下注射(SC)和肌肉注射(IM)。Omnipod® 是一种无线皮下胰岛素给药装置,可粘附在皮肤上,以皮下持续输注 (CRI) 的方式给药。狗术后使用 Omnipod® 在 1 小时内注射 1 毫克/千克氯胺酮(IB)。药代动力学(PK)显示,氯胺酮的血浆浓度介于 42 至 326.1 纳克/毫升之间。血浆浓度中位峰值为 79.5(41.9-326.1)纳克/毫升,Tmax 为 60(30-75)分钟。在相同的输注药栓后,相应的诺克他敏 PK 显示血浆药物浓度在 22.0 至 64.8 纳克/毫升之间。血浆浓度峰值中位数为 43.0(26.1-71.8)纳克/毫升,Tmax 中位数为 75 分钟。在输注后不到 1 小时的时间里,狗体内氯胺酮血浆浓度的中位峰值超过了 100 纳克/毫升。Omnipod® 系统成功地在犬术后皮下注射了氯胺酮。
{"title":"Pharmacokinetics of subcutaneous ketamine administration via the Omnipod® system in dogs","authors":"Claudia Colón,&nbsp;Peter Early,&nbsp;Karen Muñana,&nbsp;Natasha Olby,&nbsp;Christopher Mariani,&nbsp;Shelby Mancini,&nbsp;Gilad Fefer,&nbsp;Zhong Li,&nbsp;Jessica Briley,&nbsp;Kate Bailey,&nbsp;Duncan Lascelles,&nbsp;Kristen Messenger","doi":"10.1111/jvp.13440","DOIUrl":"10.1111/jvp.13440","url":null,"abstract":"<p>Ketamine is an injectable anesthetic agent with analgesic and antidepressant effects that can prevent maladaptive pain. Ketamine is metabolized by the liver into norketamine, an active metabolite. Prior rodent studies have suggested that norketamine is thought to contribute up to 30% of ketamine's analgesic effect. Ketamine is usually administered as an intravenous (IV) bolus injection or continuous rate infusion (CRI) but can be administered subcutaneously (SC) and intramuscularly (IM). The Omnipod® is a wireless, subcutaneous insulin delivery device that adheres to the skin and delivers insulin as an SC CRI. The Omnipod® was used in dogs for postoperative administration of ketamine as a 1 mg/kg infusion bolus (IB) over 1 hour (h). Pharmacokinetics (PK) showed plasma ketamine concentrations between 42 and 326.1 ng/mL. The median peak plasma concentration was 79.5 (41.9–326.1) ng/mL with a Tmax of 60 (30–75) min. After the same infusion bolus, the corresponding norketamine PK showed plasma drug concentrations between 22.0 and 64.8 ng/mL. The median peak plasma concentration was 43.0 (26.1–71.8) ng/mL with a median Tmax of 75 min. The median peak ketamine plasma concentration exceeded 100 ng/mL in dogs for less than 1 h post infusion. The Omnipod® system successfully delivered subcutaneous ketamine to dogs in the postoperatively.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"353-358"},"PeriodicalIF":1.5,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13440","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140306028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastrointestinal release site for delayed release and gelatin capsules in healthy dogs 健康狗胃肠道释放缓释胶囊和明胶胶囊的部位。
IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-22 DOI: 10.1111/jvp.13439
Charles B. Stone, Adam J. Rudinsky, Rebecca J. Urion, Simone B. March, Jenessa A. Winston

Gelatin capsules deliver their contents to the stomach, while delayed-release (DR) capsules are designed to allow delivery to the small intestine. This study evaluated the gastrointestinal release site of DR capsules in six healthy adult dogs compared to gelatin capsules. Both gelatin and DR capsules were filled with barium-impregnated polyethylene spheres (BIPS™), and following enteral administration, release site was assessed using abdominal radiographs at baseline, immediately after ingestion, 15 min post-ingestion, 30 min post-ingestion, and then every 30 min thereafter. The evaluated phases included fasted conditions (phase 1, n = 6), increased meal size (phase 2, n = 2), double encapsulation (phase 3, n = 2), and altered capsule size (phase 4, n = 1). The released site was the stomach in all phases for both capsule types. In phase 1, DR capsules had a significantly prolonged time (median 60 min, range 60–90) to release BIPS™ compared to gelatin capsules (15 min, range 15–30; p = .03). In phase 2 (full meal size), 3 (double encapsulation), and 4 (smaller capsule size) pilot studies, release time was prolonged but still occurred in the stomach. This is similar to the release site for gelatin capsules but differs from the release site for DR capsules in people. This has implications for pharmacologic outcomes for products that are affected by gastric physiology (e.g. fecal microbiota transplantation). Based on this pilot data, clinicians and researchers should not assume DR capsules will allow for intestinal delivery of contents in dogs. Future studies should be conducted on larger and varied populations of dogs.

明胶胶囊可将内容物送入胃部,而缓释(DR)胶囊则可将内容物送入小肠。与明胶胶囊相比,本研究评估了六只健康成年犬体内 DR 胶囊的胃肠道释放部位。明胶胶囊和 DR 胶囊中都填充了钡浸渍聚乙烯球(BIPS™),在肠道给药后,分别在基线、进食后立即、进食后 15 分钟、进食后 30 分钟以及之后每隔 30 分钟使用腹部 X 光片对释放部位进行评估。评估阶段包括空腹状态(第 1 阶段,n = 6)、增加饭量(第 2 阶段,n = 2)、双层封装(第 3 阶段,n = 2)和改变胶囊大小(第 4 阶段,n = 1)。两种胶囊在所有阶段的释放部位都是胃。在第 1 阶段,DR 胶囊释放 BIPS™ 的时间(中位数 60 分钟,范围 60-90)明显长于明胶胶囊(15 分钟,范围 15-30;p = 0.03)。在第 2 阶段(全餐)、第 3 阶段(双重封装)和第 4 阶段(胶囊尺寸较小)的试验研究中,释放时间有所延长,但仍在胃中释放。这与明胶胶囊的释放部位相似,但与 DR 胶囊在人体内的释放部位不同。这对受胃生理影响的产品(如粪便微生物群移植)的药理结果有影响。根据这些试验数据,临床医生和研究人员不应认为 DR 胶囊可以在狗的肠道中输送内容物。未来的研究应该在更大和更多的狗群中进行。
{"title":"Gastrointestinal release site for delayed release and gelatin capsules in healthy dogs","authors":"Charles B. Stone,&nbsp;Adam J. Rudinsky,&nbsp;Rebecca J. Urion,&nbsp;Simone B. March,&nbsp;Jenessa A. Winston","doi":"10.1111/jvp.13439","DOIUrl":"10.1111/jvp.13439","url":null,"abstract":"<p>Gelatin capsules deliver their contents to the stomach, while delayed-release (DR) capsules are designed to allow delivery to the small intestine. This study evaluated the gastrointestinal release site of DR capsules in six healthy adult dogs compared to gelatin capsules. Both gelatin and DR capsules were filled with barium-impregnated polyethylene spheres (BIPS™), and following enteral administration, release site was assessed using abdominal radiographs at baseline, immediately after ingestion, 15 min post-ingestion, 30 min post-ingestion, and then every 30 min thereafter. The evaluated phases included fasted conditions (phase 1, <i>n</i> = 6), increased meal size (phase 2, <i>n</i> = 2), double encapsulation (phase 3, <i>n</i> = 2), and altered capsule size (phase 4, <i>n</i> = 1). The released site was the stomach in all phases for both capsule types. In phase 1, DR capsules had a significantly prolonged time (median 60 min, range 60–90) to release BIPS™ compared to gelatin capsules (15 min, range 15–30; <i>p</i> = .03). In phase 2 (full meal size), 3 (double encapsulation), and 4 (smaller capsule size) pilot studies, release time was prolonged but still occurred in the stomach. This is similar to the release site for gelatin capsules but differs from the release site for DR capsules in people. This has implications for pharmacologic outcomes for products that are affected by gastric physiology (e.g. fecal microbiota transplantation). Based on this pilot data, clinicians and researchers should not assume DR capsules will allow for intestinal delivery of contents in dogs. Future studies should be conducted on larger and varied populations of dogs.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"266-273"},"PeriodicalIF":1.5,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13439","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetic characteristics of florfenicol in green sea turtles (Chelonia mydas) and hawksbill sea turtles (Eretmochelys imbricata) after intramuscular administration 绿海龟(Chelonia mydas)和玳瑁(Eretmochelys imbricata)肌肉注射氟苯尼考的药代动力学特征。
IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-22 DOI: 10.1111/jvp.13441
Pandaree Sitthiangkool, Amnart Poapolathep, Thanaphan Chomcheun, Oranee Jongkolpath, Kraisiri Khidkhan, Narumol Klangkaew, Napasorn Phaochoosak, Mario Giorgi, Saranya Poapolathep

The pharmacokinetics of florfenicol (FFC) in green sea and hawksbill sea turtles were evaluated following intramuscular (i.m.) administration at two different dosages of 20 or 30 mg/kg body weight (b.w.). This study (longitudinal design) used 5 green sea and 5 hawksbill sea turtles for the two dosages. Blood samples were collected at assigned times up to 168 h. FFC plasma samples were analyzed using validated high-performance liquid chromatography equipped with diode array detection. The pharmacokinetic analysis was performed using a non-compartment approach. The FFC plasma concentrations increased with the dosage. The elimination half-life was similar between the treatment groups (range 19–25 h), as well as the plasma protein binding (range 18.59%–20.65%). According to the surrogate PK/PD parameter (T > MIC, 2 μg/mL), the 20 and 30 mg/kg dosing rates should be effective doses for susceptible bacterial infections in green sea and hawksbill sea turtles.

本研究评估了绿海龟和玳瑁在肌肉注射 20 或 30 毫克/千克体重(b.w.)两种不同剂量的氟苯尼考(FFC)后的药代动力学。这项研究(纵向设计)使用了 5 只绿海龟和 5 只玳瑁海龟,分别服用两种剂量。在指定时间至 168 小时内采集血样。使用配备二极管阵列检测器的高效液相色谱法对 FFC 血浆样本进行分析。药代动力学分析采用非隔室方法进行。FFC 的血浆浓度随着剂量的增加而增加。各治疗组的消除半衰期(19-25 h)和血浆蛋白结合率(18.59%-20.65%)相似。根据代用 PK/PD 参数(T > MIC,2 μg/mL),20 毫克/千克和 30 毫克/千克的剂量应是绿海龟和玳瑁易感细菌感染的有效剂量。
{"title":"Pharmacokinetic characteristics of florfenicol in green sea turtles (Chelonia mydas) and hawksbill sea turtles (Eretmochelys imbricata) after intramuscular administration","authors":"Pandaree Sitthiangkool,&nbsp;Amnart Poapolathep,&nbsp;Thanaphan Chomcheun,&nbsp;Oranee Jongkolpath,&nbsp;Kraisiri Khidkhan,&nbsp;Narumol Klangkaew,&nbsp;Napasorn Phaochoosak,&nbsp;Mario Giorgi,&nbsp;Saranya Poapolathep","doi":"10.1111/jvp.13441","DOIUrl":"10.1111/jvp.13441","url":null,"abstract":"<p>The pharmacokinetics of florfenicol (FFC) in green sea and hawksbill sea turtles were evaluated following intramuscular (i.m.) administration at two different dosages of 20 or 30 mg/kg body weight (b.w.). This study (longitudinal design) used 5 green sea and 5 hawksbill sea turtles for the two dosages. Blood samples were collected at assigned times up to 168 h. FFC plasma samples were analyzed using validated high-performance liquid chromatography equipped with diode array detection. The pharmacokinetic analysis was performed using a non-compartment approach. The FFC plasma concentrations increased with the dosage. The elimination half-life was similar between the treatment groups (range 19–25 h), as well as the plasma protein binding (range 18.59%–20.65%). According to the surrogate PK/PD parameter (T &gt; MIC, 2 μg/mL), the 20 and 30 mg/kg dosing rates should be effective doses for susceptible bacterial infections in green sea and hawksbill sea turtles.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 4","pages":"300-307"},"PeriodicalIF":1.5,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to: Letter to the Editor from Malik et al.: Acute kidney injury following subcutaneous meloxicam administration 回复Malik等人致编辑的信:皮下注射美洛昔康后的急性肾损伤。
IF 1.3 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-10 DOI: 10.1111/jvp.13438
Alex Krekis, Jonathan N. King, Duncan D'Arcy-Howard, Nadene Stapleton, Jonathan Elliott, Ludovic Pelligand
{"title":"Reply to: Letter to the Editor from Malik et al.: Acute kidney injury following subcutaneous meloxicam administration","authors":"Alex Krekis,&nbsp;Jonathan N. King,&nbsp;Duncan D'Arcy-Howard,&nbsp;Nadene Stapleton,&nbsp;Jonathan Elliott,&nbsp;Ludovic Pelligand","doi":"10.1111/jvp.13438","DOIUrl":"10.1111/jvp.13438","url":null,"abstract":"","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"47 3","pages":"237-238"},"PeriodicalIF":1.3,"publicationDate":"2024-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13438","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of veterinary pharmacology and therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1